CoChat

Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea‐predominant IBS

Open access
Cremonini, F., Nicandro, J. P., Atkinson, V., Shringarpure, R., Chuang, E., Lembo, A. · 2012 · Alimentary Pharmacology & Therapeutics
Cited by 64

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Summary: Background: Patients with irritable bowel syndrome with diarrhoea ( IBS ‐ D ) experience restriction in daily activities and decreased health‐related quality of life ( QOL ). Aim: To investigate effects of alosetron on patient‐reported health‐related QOL , satisfaction and productivity in women with severe IBS ‐ D . Methods: A total of 705 women (severe IBS ‐ D , Rome II criteria) randomised to alosetron 0.5 mg QD , 1 mg QD , 1 mg BID , or placebo for 12 weeks were studied. IBSQOL , treatment satisfaction, daily activities, and lost workplace productivity ( LWP ) were evaluated at randomisation and Week 12. Results: One or more doses of alosetron significantly improved all IBSQOL domains except for sexual function from baseline vs. placebo. The magnitude of IBSQOL changes was consistent with a clinically meaningful effect. Alosetron 0.5 mg QD and 1 mg BID significantly reduced IBS interference with social/leisure activities and LWP from baseline vs. placebo [social/leisure (mean ± S.E. ) days lost: −6.7 ± 0.8, −7.0 ± 0.9, P < 0.01; LWP (mean ± S.E. ) h lost: −11.0 ± 3.3, −21.1 ± 4.1, P < 0.05 respectively]. Significantly more patients treated with alosetron reported satisfaction vs. placebo. Improvements in IBSQOL , LWP , and treatment satisfaction significantly correlated with global improvement of IBS symptoms. The incidence of adverse events with alosetron was low with constipation being the most commonly reported event. A single case of ischaemic colitis occurred, in a patient receiving alosetron 0.5 mg QD . Conclusions: In women with severe IBS ‐ D , alosetron treatment, including 0.5 mg QD , resulted in statistically significant and clinically relevant improvements in health‐related QOL , restriction of daily activities and treatment satisfaction over placebo. IBS symptom improvement corresponded with positive changes in IBSQOL , LWP and treatment satisfaction.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2012.05208.x

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 64

Metadata

Authors
Cremonini, F., Nicandro, J. P., Atkinson, V., Shringarpure, R., Chuang, E., & Lembo, A.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2012-07-10
Volume
36
Issue
5
Pages
437-448
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W2043222610
Cited by
64
References
9
FWCI
6.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea‐predominant IBS. https://app.cochat.ai/papers/10.1111/j.1365-2036.2012.05208.x
The paper
Cremonini, F., Nicandro, J. P., Atkinson, V., Shringarpure, R., Chuang, E., & Lembo, A. (2012). Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea‐predominant IBS. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2012.05208.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.